Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
0
AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion
https://www.zacks.com/stock/news/2240793/astrazeneca-azn-to-acquire-amolyt-pharma-for-1-05-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240793
Mar 14, 2024 - AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.
0
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2240290/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2240290
Mar 13, 2024 - Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
0
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
0
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2234914/astrazeneca-azn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2234914
Mar 01, 2024 - In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.
0
Top Stock Reports for Costco, Walt Disney & AstraZeneca
https://www.zacks.com/commentary/2233623/top-stock-reports-for-costco-walt-disney-astrazeneca?cid=CS-ZC-FT-research_daily-2233623
Feb 29, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN).
0
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
https://www.zacks.com/stock/news/2227354/ironwood-irwd-q4-earnings-miss-revenues-beat-marginally?cid=CS-ZC-FT-analyst_blog|earnings_article-2227354
Feb 16, 2024 - Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
0
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
0
Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication
https://www.zacks.com/stock/news/2224200/ionis-ions-eplontersen-gets-fast-track-tag-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2224200
Feb 09, 2024 - The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0